Drugs / Amoxicillin clavulanic acid
Trials 10
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial · 1 met primary | ||||||
| Phase 1 | NCT00835705 | Sep 2003 | — | Teva Pharmaceuticals USA | Completed | Met primary |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT07202052 | May 2025 → Mar 2027 expected | leukemia, non-Hodgkin lymphoma, plasma cell myeloma | Monash University | Recruiting | No outcome recorded |
| Phase 31 trial · 1 met primary | ||||||
| Phase 3 | NCT02186951 | Aug 2014 → Oct 2016 | cardiac arrest | University Hospital, Limoges | Completed | Met primary |
| Phase 47 trials | ||||||
| Phase 4 | NCT06929702 | Apr 2025 → Oct 2027 expected | — | University Hospital, Ghent | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06709196 | Jan 2025 → Jan 2027 expected | urinary bladder cancer | Rigshospitalet, Denmark | Recruiting | No outcome recorded |
| Phase 4 | NCT05079620 | Nov 2021 → Apr 2024 | aspiration pneumonia, aspiration pneumonitis | UConn Health | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT05761080 | Apr 2021 → Nov 2027 expected | appendicitis | Sant Pau Research Institute | Recruiting | No outcome recorded |
| Phase 4 | NCT02783859 | Jun 2016 → Jun 2022 | pneumonia | Menzies School of Health Research | Completed | No outcome recorded |
| Phase 4 | NCT02899507 | Sep 2013 → Mar 2015 | cardiac arrest | University Medical Centre Ljubljana | Completed | No outcome recorded |
| Phase 4 | NCT00190437 | Aug 2003 → Oct 2006 | chronic obstructive pulmonary disease | Assistance Publique - Hôpitaux de Paris | Completed | No outcome recorded |
| Comparator or background therapy8 trials | ||||||
| Phase 0 | NCT02099240 Comparator | Mar 2014 → Nov 2018 | osteomyelitis | University of Louisville | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2/3 | NCT02605122 Comparator | Apr 2016 → Mar 2018 | bacterial pneumonia | Melinta Therapeutics, Inc. | Terminated | No outcome recorded |
| Phase 3 | NCT07582549 Comparator | Dec 2025 → Dec 2027 expected | — | Tampere University Hospital | Recruiting | No outcome recorded |
| Phase 3 | NCT01733966 Comparator | May 2010 → Mar 2012 | diverticulitis of colon | Quanta Medical | Terminated | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT01015417 Comparator | May 2010 → Nov 2012 | acute cholecystitis | Centre Hospitalier Universitaire, Amiens | Completed | No outcome recorded |
| Phase 4 | NCT07015736 Background | Aug 2025 → Mar 2026 overdue | diarrheal disease, otitis media, sinusitis | Eskisehir Osmangazi University | Active not recruiting | No outcome recorded |
| Phase 4 | NCT02765217 Background | Jun 2017 → Jul 2020 | diarrheal disease | Eskisehir Osmangazi University | Completed | Met primary |
| — | NCT01715610 Comparator | May 2012 → Nov 2015 | peritonsillar abscess | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | Withdrawn | No outcome recorded Stop: Enrollment |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 18 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Amoxicillin clavulanic acid | “These include intravenous ceftriaxone, ampicillin, and amoxicillin and oral amoxicillin and amoxicillin-clavulanic acid.” NCT02605122 ↗17“comparing amoxicillin-clavulanic acid administered for 7 days to a placebo.” NCT00190437 ↗ “amoxicillin-clavulanic acid, piperacillin-tazobactam, meropenem treatment” NCT06929702 ↗ “seven day course of oral Amoxicillin-Clavulanic acid” NCT01715610 ↗ “Amoxicillin-Clavulanic Acid” NCT02099240 ↗ |
| Route | Oral | “oral form or parenteral form” NCT01015417 ↗ |